RAPP
Rapport Therapeutics, Inc. Common StockHealthcare · $2.1B market cap
Verdict
We can't put a fair value on RAPP right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow RAPP
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 8, 2026: no open-market purchases and 2 sales worth $374K. Why purchases matter
Sales
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works